A Safety and Tolerability Study of Belumosudil (KD025) Treatment in Subjects With Moderately Severe Psoriasis Vulgaris
PHASE2CompletedINTERVENTIONAL
Enrollment
8
Participants
Timeline
Start Date
April 30, 2014
Primary Completion Date
September 30, 2014
Study Completion Date
September 30, 2014
Conditions
Psoriasis Vulgaris
Interventions
DRUG
Belumosudil
Trial Locations (1)
92697
UC Irvine Health, Dept of Dermatology, Irvine
All Listed Sponsors
lead
Kadmon Corporation, LLC
INDUSTRY
NCT02106195 - A Safety and Tolerability Study of Belumosudil (KD025) Treatment in Subjects With Moderately Severe Psoriasis Vulgaris | Biotech Hunter | Biotech Hunter